130818-96-1

Basic information

• Product Name: 2-(1-Benzyl-piperidin-4-ylaMino)-ethanol
• Synonyms: 2-(1-Benzyl-piperidin-4-ylaMino)-ethanol
• CAS NO: 130818-96-1
• Molecular Formula: C₁₄H₂₂N₂O
• Molecular Weight: 234.33728
• Mol File: 130818-96-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(1-Benzyl-piperidin-4-ylaMino)-ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-Benzyl-piperidin-4-ylaMino)-ethanol(130818-96-1)
• EPA Substance Registry System: 2-(1-Benzyl-piperidin-4-ylaMino)-ethanol(130818-96-1)

Safety Data

• Hazardous Substances Data: 130818-96-1(Hazardous Substances Data)

Usage

Structure

A derivative of ethanol with a piperidine ring and a benzyl group attached

Pharmacological properties

Potential applications in the field of medicine, particularly for the treatment of disorders such as anxiety, depression, and pain

Role in pharmaceutical synthesis

Common intermediate or precursor in the synthesis of various pharmaceuticals

Structural similarity

Similarity to other compounds with known pharmacological activities, making it a target for further research and development in medicinal chemistry.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 141-43-5 ethanolamine 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 540-51-2 2-bromoethanol 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 

Downstream Products

• 198823-19-7 N-(3-cyanophenyl)-N'-(2-hydroxyethyl)-N'-(1-benzylpiperidin-4-yl)urea 
• 198823-20-0 3-[3-(1-benzyl-piperidin-4-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile 
• 130818-97-2 3-(1-benzylpiperidin-4-yl)oxazolidin-2-one 

Relevant articles and documents

Identification of a potent, selective, and orally active leukotriene A 4 hydrolase inhibitor with anti-inflammatory activity

LTA4H is a ubiquitously distributed 69 kDa zinc-containing cytosolic enzyme with both hydrolase and aminopeptidase activity. As a hydrolase, LTA4H stereospecifically catalyzes the transformation of the unstable epoxide LTA4 to the diol LTB4, a potent chemoattractant and activator of neutrophils and a chemoattractant of eosinophils, macrophages, mast cells, and T cells. Inhibiting the formation of LTB4 is expected to be beneficial in the treatment of inflammatory diseases such as inflammatory bowel disease (IBD), asthma, and atherosclerosis. We developed a pharmacophore model using a known inhibitor manually docked into the active site of LTA4H to identify a subset of compounds for screening. From this work we identified a series of benzoxazole, benzthiazole, and benzimidazole inhibitors. SAR studies resulted in the identification of several potent inhibitors with an appropriate cross-reactivity profile and excellent PK/PD properties. Our efforts focused on further profiling JNJ 27265732, which showed encouraging efficacy in a disease model relevant to IBD.

BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS

Leukotriene A4 hydrolase (LTA4H) inhibitors of formula I, compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation, wherein X is selected from the group consisting of NR5, O, and S, with R5 being one of the H and CH3; Y is selected from the group consisting of CH2 and O; R4 is selected from the group consisting of H, OCH3, Cl, F, Br, I, OH, NH2, CN, CF3.

N-(AMIDINOPHENYL) CYCLOUREA ANALOGS AS FACTOR XA INHIBITORS

The present application describes N-(amidinophenyl)cyclourea analogs of formula I: STR1 which are useful as inhibitors of factor Xa.

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Initial sar studies

In this report we discuss the design, synthesis, and validation of a novel series of cyclic urea inhibitors of the blood coagulation protein Factor Xa. This work culminates in compound 11, a monoamidine inhibitor of fXa employing a new S4 ligand that reduces the cationic character of these analogs. Compound 11 represents a lead for a series of more potent and selective inhibitors.

Molecular features associated with polyamine modulation of NMDA receptors

The effect of 1,3-diamines on basal and spermine-stimulated [3H]MK-801 binding was investigated. Systematic variations in the molecular parameters revealed that, in general, lipophilic 1,3-diamines inhibited and hydrophilic 1,3-diamines enhance

Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

The invention relates to cyclic urea derivatives of general formula I STR1 wherein Ra, Rb, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.